Skip to main content
Top
Published in: Infection 6/2017

01-12-2017 | Original Paper

The dangers of extreme body mass index values in patients with Clostridium difficile

Authors: Brian H. Nathanson, Thomas L. Higgins, William T. McGee

Published in: Infection | Issue 6/2017

Login to get access

Abstract

Purpose

To examine the association between body mass index (BMI) and in-hospital mortality in patients presenting with Clostridium difficile infections in emergency department visits (ED) in the USA. Infected patients with extreme BMIs may have an elevated mortality risk, but prior studies examining this question have been too small to reach definitive conclusions.

Methods

Data were from the Nationwide Emergency Department Sample (NEDS), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality during 2012. NEDS records emergency department (ED) visits across the USA and provides statistical sampling weights to approximate a nationally representative sample of US hospital-based EDs. Inclusion criteria were adults age 18 or older with an ICD-9 code for C. difficile infection (008.45) and a documented body mass index ICD-9 V code (V85.x). Logistic regression was used to predict mortality after adjusting for demographic variables and chronic comorbidities defined by Elixhauser.

Results

A weighted sample of 22,937 ED visits met all inclusion criteria. The cohort’s mean age was 66. 64.6% were female. The unadjusted mortality rate was 6.5%. Patients with a BMI < 19 kg/m2 had an adjusted odds ratio of 2.73; 95% CI (1.80, 4.16), p < 0.001 compared to patients with a BMI of 19.0–4.9 kg/m2 (the referent category). In obese patients, only BMI values >40 kg/m2 were associated with significantly greater mortality risk.

Conclusion

Being underweight (BMI < 19) or morbidly obese (BMI > 40) was associated with increased risk of in-hospital mortality in patients presenting with C. difficile infections.
Literature
1.
2.
go back to reference Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile–associated diarrhea: a review. Arch Intern Med. 2001;161:525–33.CrossRefPubMed Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile–associated diarrhea: a review. Arch Intern Med. 2001;161:525–33.CrossRefPubMed
3.
go back to reference Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: new challenges from an established pathogen. Clev Clin J Med. 2006;1:187.CrossRef Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: new challenges from an established pathogen. Clev Clin J Med. 2006;1:187.CrossRef
4.
go back to reference Kelly CP, LaMont JT. Clostridium difficile—more difficult than ever. New Engl J Med. 2008;359:1932–40.CrossRefPubMed Kelly CP, LaMont JT. Clostridium difficile—more difficult than ever. New Engl J Med. 2008;359:1932–40.CrossRefPubMed
5.
go back to reference Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother. 2003;51:1339–50.CrossRefPubMed Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother. 2003;51:1339–50.CrossRefPubMed
6.
go back to reference Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA. 2015;313:398–408.CrossRefPubMed Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA. 2015;313:398–408.CrossRefPubMed
7.
go back to reference McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. New Engl J Med. 1989;320:204–10.CrossRefPubMed McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. New Engl J Med. 1989;320:204–10.CrossRefPubMed
8.
go back to reference Nanwa N, Kendzerska T, Krahn M, Kwong JC, Daneman N, Witteman W, Mittmann N, Cadarette SM, Rosella L, Sander B. The economic impact of Clostridium difficile infection: a systematic review. Am J Gastroenterol. 2015;110:511–9.CrossRefPubMed Nanwa N, Kendzerska T, Krahn M, Kwong JC, Daneman N, Witteman W, Mittmann N, Cadarette SM, Rosella L, Sander B. The economic impact of Clostridium difficile infection: a systematic review. Am J Gastroenterol. 2015;110:511–9.CrossRefPubMed
9.
go back to reference Gerding DN, Lessa FC. The epidemiology of Clostridium difficile infection inside and outside health care institutions. Infect Dis Clin N Am. 2015;29:37–50.CrossRef Gerding DN, Lessa FC. The epidemiology of Clostridium difficile infection inside and outside health care institutions. Infect Dis Clin N Am. 2015;29:37–50.CrossRef
10.
go back to reference Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist. 2014;7:63–72.PubMedPubMedCentral Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist. 2014;7:63–72.PubMedPubMedCentral
11.
go back to reference Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harmsen WS, Zinsmeister AR. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol. 2012;107:89–95.CrossRefPubMed Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harmsen WS, Zinsmeister AR. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol. 2012;107:89–95.CrossRefPubMed
12.
go back to reference Bishara J, Farah R, Mograbi J, Khalaila W, Abu-Elheja O, Mahamid M, Nseir W. Obesity as a risk factor for Clostridium difficile infection. Clin Infect Dis. 2013;3:cit280. Bishara J, Farah R, Mograbi J, Khalaila W, Abu-Elheja O, Mahamid M, Nseir W. Obesity as a risk factor for Clostridium difficile infection. Clin Infect Dis. 2013;3:cit280.
13.
go back to reference Leung J, Burke B, Ford D, Garvin G, Korn C, Sulis C, Bhadelia N. Possible association between obesity and Clostridium difficile infection. Emerg Infect Dis. 2013;19:1791–8.CrossRefPubMedPubMedCentral Leung J, Burke B, Ford D, Garvin G, Korn C, Sulis C, Bhadelia N. Possible association between obesity and Clostridium difficile infection. Emerg Infect Dis. 2013;19:1791–8.CrossRefPubMedPubMedCentral
14.
go back to reference Punni E, Pula JL, Asslo F, Baddoura W, DeBari VA. Is obesity a risk factor for Clostridium difficile infection? Obes Res Clin Pract. 2015;9:50–4.CrossRefPubMed Punni E, Pula JL, Asslo F, Baddoura W, DeBari VA. Is obesity a risk factor for Clostridium difficile infection? Obes Res Clin Pract. 2015;9:50–4.CrossRefPubMed
15.
go back to reference Trivedi V, Bavishi C, Jean R. Impact of obesity on sepsis mortality: a systematic review. J Crit Care. 2015;30:518–24.CrossRefPubMed Trivedi V, Bavishi C, Jean R. Impact of obesity on sepsis mortality: a systematic review. J Crit Care. 2015;30:518–24.CrossRefPubMed
16.
go back to reference Nie W, Zhang Y, Jee SH, Jung KJ, Li B, Xiu Q. Obesity survival paradox in pneumonia: a meta-analysis. BMC Med. 2014;12:1.CrossRef Nie W, Zhang Y, Jee SH, Jung KJ, Li B, Xiu Q. Obesity survival paradox in pneumonia: a meta-analysis. BMC Med. 2014;12:1.CrossRef
18.
go back to reference Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.CrossRefPubMed Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.CrossRefPubMed
19.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed
20.
go back to reference Sturm R. Increases in morbid obesity in the USA: 2000–2005. Public Health. 2007;j121:492–6.CrossRef Sturm R. Increases in morbid obesity in the USA: 2000–2005. Public Health. 2007;j121:492–6.CrossRef
21.
go back to reference Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA. 2005;293:1861–7.CrossRefPubMed Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA. 2005;293:1861–7.CrossRefPubMed
22.
go back to reference Padwal R, Leslie WD, Lix LM, Majumdar SR. Relationship among body fat percentage, body mass index, and all-cause mortality. Ann Intern Med. 2016;164:532.CrossRefPubMed Padwal R, Leslie WD, Lix LM, Majumdar SR. Relationship among body fat percentage, body mass index, and all-cause mortality. Ann Intern Med. 2016;164:532.CrossRefPubMed
23.
go back to reference Alpert MA, Omran J, Mehra A, Ardhanari S. Impact of obesity and weight loss on cardiac performance and morphology in adults. Prog Cardiovasc Dis. 2014;56:391–400.CrossRefPubMed Alpert MA, Omran J, Mehra A, Ardhanari S. Impact of obesity and weight loss on cardiac performance and morphology in adults. Prog Cardiovasc Dis. 2014;56:391–400.CrossRefPubMed
24.
go back to reference Falagas ME, Athanasoulia AP, Peppas G, Karageorgopoulos DE. Effect of body mass index on the outcome of infections: a systematic review. Obes Rev. 2009;10:280–9.CrossRefPubMed Falagas ME, Athanasoulia AP, Peppas G, Karageorgopoulos DE. Effect of body mass index on the outcome of infections: a systematic review. Obes Rev. 2009;10:280–9.CrossRefPubMed
25.
go back to reference Thomas DR. Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr. 2007;26:389–99.CrossRefPubMed Thomas DR. Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr. 2007;26:389–99.CrossRefPubMed
26.
go back to reference Mulki R, Baumann AJ, Alnabelsi T, Sandhu N, Alhamshari Y, Wheeler DS, Perloff S, Katz PO. Body mass index greater than 35 is associated with severe Clostridium difficile infection. Aliment Pharmacol Ther. 2017;45:75–81.CrossRefPubMed Mulki R, Baumann AJ, Alnabelsi T, Sandhu N, Alhamshari Y, Wheeler DS, Perloff S, Katz PO. Body mass index greater than 35 is associated with severe Clostridium difficile infection. Aliment Pharmacol Ther. 2017;45:75–81.CrossRefPubMed
27.
go back to reference Hall RG, Payne KD, Bain AM, Rahman AP, Nguyen ST, Eaton SA, Busti AJ, Vu SL, Bedimo R. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med. 2008;121:515–8.CrossRefPubMedPubMedCentral Hall RG, Payne KD, Bain AM, Rahman AP, Nguyen ST, Eaton SA, Busti AJ, Vu SL, Bedimo R. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med. 2008;121:515–8.CrossRefPubMedPubMedCentral
28.
go back to reference Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections. Am J Gastroenterol. 2013;108:478–98.CrossRefPubMed Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections. Am J Gastroenterol. 2013;108:478–98.CrossRefPubMed
29.
go back to reference Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother. 2012;67:1305–10.CrossRefPubMed Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother. 2012;67:1305–10.CrossRefPubMed
30.
31.
go back to reference Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23:858–83.CrossRefPubMedPubMedCentral Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23:858–83.CrossRefPubMedPubMedCentral
32.
go back to reference Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet. 2010;375:248–51.CrossRefPubMed Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet. 2010;375:248–51.CrossRefPubMed
33.
go back to reference Center for Disease Control and Prevention. Antibiotic resistance threats in the United States. Atlanta: CDC; 2013. Center for Disease Control and Prevention. Antibiotic resistance threats in the United States. Atlanta: CDC; 2013.
34.
go back to reference Campbell R, Dean B, Nathanson B, Haidar T, Strauss M, Thomas S. Length of stay and hospital costs among high-risk patients with hospital-origin Clostridium difficile-associated diarrhea. J Med Econ. 2013;16:440–8.CrossRefPubMed Campbell R, Dean B, Nathanson B, Haidar T, Strauss M, Thomas S. Length of stay and hospital costs among high-risk patients with hospital-origin Clostridium difficile-associated diarrhea. J Med Econ. 2013;16:440–8.CrossRefPubMed
Metadata
Title
The dangers of extreme body mass index values in patients with Clostridium difficile
Authors
Brian H. Nathanson
Thomas L. Higgins
William T. McGee
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 6/2017
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-017-1036-x

Other articles of this Issue 6/2017

Infection 6/2017 Go to the issue